Resistance to chemotherapy, enhanced proliferation, invasion, angiogenesis, and
metastasis (RPIAM) represent major obstacles that limit the efficacy of cancer treatment …

One approach to improve the targeted therapeutic efficiency of lung cancer is to deliver
drugs using nano-scaled systems. In this study, RGD peptide-modified, paclitaxel (PTX) …

Purpose: Co-delivery of drugs to achieve the synergistic anticancer effect is a promising
strategy for lung cancer therapy. The purpose of this research is to develop a doxorubicin …

Overexpression of nuclear factor E2–related factor 2 (Nrf2) contributes to the
chemotherapeutic resistance of non–small-cell lung cancer (NSCLC). Docetaxel (DTX) is …

Purpose Non-small cell lung cancer (NSCLC) therapy faces the barriers including drug
resistance. A transferrin-functionalized protein-lipid hybrid nanoparticle (PLHN) was …

Polymer microspheres are attracting wide attention in localized cancer therapy owing to the
excellent biocompatibility and drug loading capacity, controllable biodegradation speeds …

Erlotinib-HCl is a quinazoline derivative used as a drug in the therapy of non-small-cell lung
cancer. The present study was conducted to compare the subacute toxicity induced by …

Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …

The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and
erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung …

Non-small cell lung cancer (NSCLC) is a global concern as one of the leading causes of
cancer deaths. The treatment options for NSCLC are limited to systemic chemotherapy …